Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

Major Program(s) or Research Group(s)

  • Gastrointestinal and Other Cancers
  • Phase 0/I/II Cancer Prevention Clinical Trials Program

Sponsor

National Cancer Institute (NCI)

Status

Active, not recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT02273362

This pilot phase I/II trial studies the best dose of erlotinib hydrochloride and to see how
well it works in preventing liver cancer in patients with scarring (cirrhosis) of the liver.
Erlotinib hydrochloride may help to inhibit the development of fibrous tissue and prevent
liver cancer from forming in patients with cirrhosis of the liver.

Intervention

Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Erlotinib

Condition

Cirrhosis, Hepatocellular Carcinoma

Investigators

Kenneth K Tanabe

See list of participating sites